Fulgent Genetics, Inc. Q2 2026 Earnings Recap

Fulgent Genetics shares dropped 15.7% after the quarter as investors reacted negatively to significant deceleration in the core Precision Diagnostics segment, coupled with continued operational challenges in revenue recognition that pressured near-term revenue visibility and margins.

Key Takeaways

• Laboratory services revenue grew 4% year-over-year to $85.4 million, boosted by recent acquisitions Bako and StrataDX.
• Precision Diagnostics revenue declined 13% year-over-year to $41.5 million, highlighting a key business segment weakness.
• Sequential revenue in Precision Diagnostics increased 3%, but ongoing issues in billing and revenue cycle management delayed claim processing and reduced recognized revenue.
• Management prioritized resolving revenue cycle inefficiencies but provided a cautious outlook given these operational headwinds.
• Encouraging progress in the therapeutic development pipeline, including completion of Phase II data for FID-007 and advancement of FID-022 to Phase I dose escalation, but these remain early-stage with no near-term revenue impact.